The drugs identified for negotiation in the second round include: Ozempic, Wegovy and other GPL-inhibitors are in high demand in the U.S. Due to that demand, Medicare covering them for diabetes ...
Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key government program, Medicare, doesn’t cover the drugs for obesity. Meanwhile, some big employers are adding ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...
The Food and Drug Administration said on Friday that there is no longer a shortage of drugs like Wegovy and Ozempic. The semaglutide known as Ozempic is intended to be used for people with diabetes.
Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...
The company's blockbuster semaglutide drugs, Wegovy for weight loss and Ozempic ... REUTERS / Reuters Another potential headwind is Medicare drug pricing negotiations. The earnings report is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results